> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bayer’s Aliqopa Withdrawn Over Failed Confirmation
- URL: https://www.fdaweb.com/bayers-aliqopa-withdrawn-over-failed-confirmation/
- Published: 2024-03-18T12:00:00.000Z
- Updated: 2026-09-14T14:25:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156575

*Federal Register* notice: FDA is withdrawing the approval of Bayer’s NDA for relapsed follicular lymphoma drug Aliqopa (copanlisib) after the company requested the action in response to a required postmarketing trial that did not verify the drug’s clinical benefit. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-03-18/pdf/2024-05619.pdf?ref=fdaweb.com).